Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion by Ricci, Zaccaria et al.
Open Access
Available online http://ccforum.com/content/10/2/R67
Page 1 of 7
(page number not for citation purposes)
Vol 10 No 2 Research
Solute removal during continuous renal replacement therapy in 
critically ill patients: convection versus diffusion
Zaccaria Ricci1, Claudio Ronco2, Alessandra Bachetoni3, Giuseppe D'amico4, Stefano Rossi4, 
Elisa Alessandri1, Monica Rocco1 and Paolo Pietropaoli5
1Department of Intensive Care, Policlinico Umberto I, Rome, Italy
2Department of Nephrology, Dialysis and Transplantation, St Bortolo Hospital, Vicenza, Italy
3Laboratory of Clinical Chemistry, Policlinico Umberto I, Rome, Italy
4Department of Intensive Care, Policlinico Umberto I, Rome, Italy
5Department of Intensive Care, Policlinico Umberto I, Rome, Italy
Corresponding author: Zaccaria Ricci, z.ricci@libero.it
Received: 31 Jan 2006 Revisions requested: 23 Jan 2006 Revisions received: 14 Mar 2006 Accepted: 19 Mar 2006 Published: 28 Apr 2006
Critical Care 2006, 10:R67 (doi:10.1186/cc4903)
This article is online at: http://ccforum.com/content/10/2/R67
© 2006 Ricci et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction The best modality, for continuous renal
replacement therapy (CRRT) is currently uncertain and it is
poorly understood how transport of different solutes, whether
convective or diffusive, changes over time.
Methods We conducted a prospective cross over study in a
cohort of critically ill patients, comparing small (urea and
creatinine) and middle (β2  microglobulin) molecular weight
solute clearance, filter lifespan and membrane performance over
a period of 72 hours, during 15 continuous veno-venous dialysis
(CVVHD) and 15 continuous veno-venous hemofiltration
(CVVH)sessions. Both modalities were administered based on
a prescription of 35 ml/kg/h and using polyacrylonitrile filters.
Results Median filter lifespan was significantly longer during
CVVHD (37 hours, interquartile range (IQR) 19.5 to 72.5) than
CVVH (19 hours, IQR 12.5 to 28) (p = 0.03). Median urea time
weighted average (TWA) clearances were not significantly
different during CVVH (31.6 ml/minute, IQR 23.2 to 38.9) and
CVVHD (35.7 ml/minute, IQR 30.1 to 41.5) (p = 0.213). Similar
results were found for creatinine: 38.1 ml/minute, IQR 28.5 to
39, and 35.6 ml/minute, IQR 26 to 43 (p = 0.917), respectively.
Median β2m TWA clearance was higher during convective (16.3
ml/minute, IQR 10.9 to 23) than diffusive (6.27 ml/minute, IQR
1.6 to 14.9) therapy; nonetheless this difference did not reach
statistical significance (p  = 0.055). Median TWA adsorptive
clearance of β2m appeared to have scarce impact on overall
solute removal (0.012 ml/minute, IQR -0.09 to 0.1, during
hemofiltration versus -0.016 ml/minute, IQR -0.08 to 0.1 during
dialysis; p = 0.79). Analysis of clearance modification over time
did not show significant modifications of urea, creatinine and
β2m clearance in the first 48 hours during both treatments. In the
CVVHD group, the only significant difference was found for β2m
between 72 hours and baseline clearance.
Conclusion Polyacrylonitrile filters during continuous
hemofiltration and continuous hemodialysis delivered at 35 ml/
kg/h are comparable in little and middle size solute removal.
CVVHD appears to warrant longer CRRT sessions. The
capacity of both modalities for removing such molecules is
maintained up to 48 hours.
Introduction
There has been growing interest in the effects of continuous
renal replacement therapy (CRRT) on the course of acute
renal failure (ARF) in critically ill patients, based on the
assumption that removal of several molecules, including ure-
mic toxins and inflammatory mediators, might improve out-
come [1,2]. Different prospective trials have provided
conflicting results regarding what dose should be applied in
the extracorporeal therapy of ARF [3-5]. Furthermore, there is
wide variation in the way in which CRRT is practiced around
the world. In addition to dosing, timing, membranes and fluids,
the mode of CRRT varies. Many intensivists and nephrologists
β2m = β2 microglobulin; ARF = acute renal failure; CRRT = continuous renal replacement therapy; CVVH = continuous veno-venous hemofiltration; 
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prefer to use continuous veno-venous hemofiltration (CVVH)
in the belief that pure convection will remove more larger mol-
ecules than diffusion-based continuous veno-venous dialysis
(CVVHD). Others argue that CVVHD is easier and, given the
lack of comparative evidence, prefer this mode. Still a third
school favors continuous veno-venous hemodiafiltration
(CVVHDF) on the basis that without evidence, providing both
modes is safest. Many studies have used continuous hemofil-
tration for this purpose, following the expectation that a wider
range of molecular weights can be cleared with predominantly
convective rather than predominantly diffusive techniques [3-
5]. However, this notion, although based on several in vitro
experiments and experience in chronic dialysis [6], has never
been tested by a comparative study during the course of con-
tinuous extracorporeal treatment.
We recently showed that CRRT dose, estimated as urea clear-
ance, is highly predictable, regardless of prescription and
selected modality [7]. During CRRT, nonetheless, many varia-
bles may affect the effective delivery of treatment dose: if the
molecular weight of different solutes is certainly an important
aspect, the time factor appears to be an essential variable as
well; interruptions cause a clinically significant therapy down-
time and increase discrepancy between prescription and
effective delivery [8]. A recent single center study showed that
mean filter life in critically ill patients was only 16 hours and
that clotting was the primary reason for shortened filter life [9].
Furthermore, progressive filter clotting and clogging may
greatly reduce, over time, filter performance and solute
removal. Adsorption is another mechanism of mediator
removal for some membranes, particularly for polyacrylonitrile
membranes during hemofiltration [10]. We conducted a pro-
spective cross over study in a cohort of critically ill patients,
comparing small and middle molecular weight solute clear-
ance, filter lifespan and membrane performance over a period
of 72 hours during CVVHD and CVVH. Urea and creatinine
were used as markers of small molecular weight solutes and
β2 microglobulin (β2m) as a surrogate for middle molecular
weight solutes.
Materials and methods
We prospectively collected data from 30 consecutive CRRT
treatments administered to 15 critically ill patients (Table 1)
with ARF. The study protocol was approved by the local ethics
committee. CRRT was started in each case when a 'Failure'
level was indicated according to RIFLE criteria. RIFLE is an
acronym indicating Risk of renal dysfunction; Injury to the kid-
ney; Failure of kidney function, Loss of kidney function and
End-stage kidney disease [11]. Thus, criteria were a three-fold
increase of creatinine level with respect to baseline, or a cre-
atinine concentration over 4 mg/dl, or oligoanuria lasting for
24 hours.
According to the mean of a previously described 'Calculator',
CRRT was prescribed for both CVVHD and CVVH to a dose
of single pool Kt/V (clearance (K) × time (t)/urea volume of dis-
tribution (V)) of 1.4, which approaches an operative prescrip-
tion of 35 ml/kg/h [7]. Lactate buffered solutions were used.
The replacement solution during CVVH was infused both
before and after the filter to keep the plasmatic filtration frac-
tion below 20%. Net ultrafiltration (UF) was determined based
on clinical needs.
Anticoagulation was performed, according to protocol, with an
unfractionated pre-filter heparin infusion at a dose of 5 to 10
IU/kg/h. No anticoagulant infusion was administered if one of
the following was present: ongoing bleeding; major hemor-
rage in the last seven days; an international normalized ratio
(INR) or a partial thromboplastin time ratio (PTTr) higher than
2; or a platelet count lower than 40 × 103/mm3. Treatments
were interrupted only at filter clotting (filter drop pressure over
300 mmHg) or clogging (transmembrane pressure over 350
mmHg).
A Prismaflex machine (Gambro-Dasco, Mirandola (Mo) Italy)
and 0.9 m2 AN69 hollow fibre filters (Multiflow 100, Hospal,
Lyon, France) were used for all treatments (UF coefficient with
blood, 25 ml/h/mmHg × m2; cutoff point, 40 kDa). Only the
first two treatments for each patient were considered for the
study; after the criteria for CRRT were established, patients
received one CVVH and one CVVHD session, in a random
sequence. The cross over design of the study allowed us to
compare convective and diffusive clearances and to avoid
eventual confounding factors deriving from different vascular
access, anticoagulation requirements, net UF needs or other
unknown elements (Tables 1 and 2).
Samples were withdrawn at treatment start (T0), after 12
hours (T1) and then every 24 hours (T2, T3, T4). One sample
withdrawn at the 72nd hour and three at the 96th hour of
CVVH and one at the 120th hour of CVVHD were excluded
from the analysis of clearance modification over time.
Samples for urea, creatinine and β2m measurement were
taken simultaneously from the arterial blood line (before the
pre-filter re-infusion site during CVVH), from the venous blood
line (after the post-filter re-infusion line during CVVH) and from
the effluent line (df). Blood samples were then centrifuged and
stored at -80°C together with effluent samples. Quantitative
measures of β2m were obtained by microparticle enzyme
immunoassay.
Urea, creatinine and β2m clearances were calculated from the
dialysate side using the formula:
K = 2 × ([X]df × Qdf)/([X]I + [X]O)
where [X]df is the concentration of a given solute X in the dia-
filtrate; [X]I is the concentration of the examined solute X in the
plasma entering the filter; [X]O is the plasma concentration ofAvailable online http://ccforum.com/content/10/2/R67
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the examined solute X in the venous blood line; and Qdf is the
diafiltrate (effluent) flow rate (ml/minute).
Adsorptive clearance (KAD) was calculated only for β2m as:
KAD = MAD/[X]I
where MAD is the mass removal rate by membrane adsorption,
which was calculated as:
MAD = Mt - Mdf
where Mt is total mass removal rate (pg/minute):
Mt = MI - MO
Mdf is mass removal rate by UF or dialysis:
Mdf = Qdf × [X]df
MI is inlet mass rate (mg/minute):
MI = QI × [X]I
MO is outlet mass rate (pg/minute):
MO = QO × [X]O
QI is inlet plasma flow (ml/minute):
QI = QB(1 - hematocrit)
QO is outlet plasma flow (ml/minute):
QO = QI - Qdf
and Qdf is the effluent flow (ml/minute) and QB is prescribed
blood flow (ml/minute).
Statistical analysis
Statistical analysis was performed with the GraphPad Prism
4.03 software package (GraphPad Software, San Diego, CA,
USA). Data are reported as median ± interquartile range
(IQR). Comparative circuit survival for each modality was
assessed using log-rank tests with Kaplan-Meier analysis.
Fisher exact test and Mann-Whitney tests when appropriate
were used to compare clinical features of the patients and pre-
scribed settings during CVVH and CVVHD. Time-weighted
average (TWA) clearances (excluding the baseline value) were
calculated for the two techniques and used for comparing
CVVH and CVVHD by Mann-Whitney test. To evaluate filter
performance over time, clearances of each solute were then
analyzed separately for CVVH and CVVHD by Friedman's test.
Post hoc Dunn tests were used to identify which time points
were associated with change. A p value less than 0.05 was
considered significant.
Table 1
Clinical characteristics and vascular access features of examined patients
Total number of patients 15
Admission diagnosis
Abdominal surgery 5
Pneumonia 5
Trauma 4
Acute myocardial infarction 1
SAPS IIa 61 (15–80)
Agea 50 (25–78)
Weighta 75 (58–89)
Males/females 10/5
Catheter placement
Femoral 9
Internal jugular 3
Subclavian 3
Catheter size
12 French 7
13.5 French 8
aSimplified Acute Physiology Score (SAPS) II, age and weight are median with interquartile range in parentheses.Critical Care    Vol 10 No 2    Ricci et al.
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Results
We examined 30 treatments (15 CVVH and 15 CVVHD)
administered to 15 consecutive critically ill patients. Clinical
characteristics of the patients and circuit pressures at the
moment the session was started were compared (Tables 1
and 2): no significant differences were observed for patient
weight, age, severity of illness scores (Simplified Acute Physi-
ology Score II), anticoagulation parameters (international nor-
malized ratio, partial thromboplastin time ratio, Antithrombin III,
heparin infusion prescription, net UF requirements, blood flow
rate prescription, vascular access conditions (cannulation site,
internal diameter, access and return pressure) and reasons to
stop treatment (clogging/clotting).
Median filter lifespan was significantly longer during CVVHD
(37 hours, IQR 19.5 to 72.5) than CVVH (19 hours, IQR 12.5
to 28) (p = 0.03; Figure 1). Median urea TWA clearances
were not significantly different between CVVH (31.6 ml/
minute, IQR 23.2 to 38.9) and CVVHD (35.7 ml/minute, IQR
30.1 to 41.5) (p = 0.213). Similar results were found for cre-
atinine: 38.1 ml/minute, IQR 28.5 to 39, and 35.6 ml/minute,
IQR 26 to 43 (p = 0.917), respectively. Median β2m TWA
clearance was higher during convective (16.3 ml/minute, IQR
10.9 to 23) than diffusive (6.27 ml/minute, IQR 1.6 to 14.9)
therapy; however, this difference was not statistically signifi-
cant (p = 0.055). Median TWA adsorptive clearance of β2m
appeared to be superior during hemofiltration (0.012 ml/
minute, IQR -0.09 to 0.1, versus -0.016 ml/minute, IQR -0.08
to 0.1, during dialysis), but again without significant differ-
ences (p = 0.79; Figure 2a–d).
Analysis of clearance modification over time was performed
separately for predominantly convective and predominantly
diffusive treatments. During CVVH, available data did not
show significant modifications of urea, creatinine and β2m
clearance in the first 48 hours. During CVVHD, the only signif-
icant difference was found between the T4 (72 hours) and
baseline clearance of β2m. Results for each solute are shown
in Figure 3a–c.
Table 2
Coagulation parameters of examined patients and machine settings at the start of each treatment
Parameter CVVH CVVHD P-value
INR 1.21 (0.98–1.95) 1.4 (0.95–2) NS
PTTr 1.5 (0.85–2.1) 1.19 (0.87–1.89) NS
PLT count × 1,000 248 (56–434) 231 (65–358) NS
Antithrombin III (%) 75 (89-56) 69 (94-58) NS
Hematocrit (%) 25 (21.5–35) 24.7 (22–34.5) NS
Heparin (U/h) 500 (150–750) 500 (200–800) NS
QB 150 (110–180) 135 (115–165) NS
QREP (ml/h) --
Pre 1,450 (800–1,700)
Post 1,500 (1,000–1,950)
QDIAL (ml/h) - 2,150 (1,800–2,800) -
Net UF 150 (50–350) 165 (45–300) NS
Access pressure (mmHg) -75 (-35 to -170) -82 (-40 to -155) NS
Return pressure (mmHg) 90 (65–178) 82 (46–160) NS
Clotting/clogging 9/6 7/8 NS
Data are presented as median with interquartile range in parentheses. CVVH, continuous veno-venous hemofiltration; CVVHD, continuous veno-
venous dialysis; INR, international normalized ratio; NS, not significant; PLT, platelets; PTTr, partial thromboplastin time ratio; QB, blood flow; QREP, 
replacement solution flow (pre/post, pre-filter/post-filter re-infusion); QDIAL, dialysate flow; UF, ultrafiltration.
Figure 1
Kaplan-Meier analysis of circuit survival for continuous veno-venous  hemofiltration (CVVH) and continuous veno-venous dialysis (CVVHD) Kaplan-Meier analysis of circuit survival for continuous veno-venous 
hemofiltration (CVVH) and continuous veno-venous dialysis (CVVHD).Available online http://ccforum.com/content/10/2/R67
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Discussion
During CRRT, the ideal membrane should remove the widest
range of waste products and inflammation mediators peaking
in the blood of anuric septic patients. At the start of treatment,
when the filter is fresh, hemofiltration is probably the modality
that provides, through convective transport, the maximum sol-
ute removal allowed by the filter pore cutoff. It has never been
evaluated, however, whether filter performance is maintained
over time during CRRT. Furthermore, recent preliminary stud-
ies have questioned whether, when using polyacrylonitrile or
high porosity membranes, hemofiltration is superior to diffu-
sion at eliminating high molecular weight molecules [12-14].
Our study aimed to give some answers to these issues by
comparing the clearance of small (urea and creatinine) and
middle (β2m) size molecules during the course of CVVH and
CVVHD. Urea and creatinine are the classic serum markers
measured during ARF to monitor the progression of the dis-
ease or the efficacy of extracorporeal treatment. β2m is an
11,600 Dalton molecule that is normally present in most bio-
logical fluids; it is filtered by glomeruli and is catabolised after
proximal tubular reabsorption. Serum β2m levels are elevated
up to 60-fold in patients undergoing dialysis for chronic renal
failure and β2m amyloid deposits are responsible for several
musculoskeletal manifestations in these patients [15]. The role
of this substance during ARF is unknown, but we used it as a
marker for middle molecular weight molecules (such as,
endothelin, bradykinin, IL1, IL8, complement factors C3a/C5a)
that range between 10 and 50 kDa.
During the study we used polyacrylonitrile filters, which are
biocompatible synthetic membranes with both a high ultrafil-
tration coefficient (Kuf) and a very good diffusive solute trans-
fer: these filters have a relatively high cutoff point and are also
considered to have good adsorptive properties [10]. The pre-
scribed dose for both modalities was a Kt/V of 1.4, which
approaches a urea clearance of 35 ml/kg/h. This dose was
recently described to improve the outcome of a large popula-
tion of critically ill patients, if administered by CVVH, and was
suggested by the Surviving Sepsis Campaign guidelines as
the recommended prescription during septic ARF [3,16].
During CVVH, we delivered re-infusion solution partially before
and partially after the filter: the rate of pre-/post-dilution was
calculated after the blood flow was set in order to keep the
plasmatic filtration fraction below 20%. However, considering
that the median weight of patients was 75 kg and that the
median pump blood flow was 150 ml/minute during CVVH,
high UF rates were always necessary, even using predilution.
This condition caused significantly higher transmembrane
pressure values during CVVH than during CVVHD (data not
shown), which could partially explain the fact that continuous
dialysis sessions were correlated with a longer filter lifespan
than in hemofiltration.
As expected, the clearance of small molecules was very similar
between the two groups and this confirmed that the operative
prescription was correct and comparable. Elimination of β2m
was superior during hemofiltration even if, after adjustment for
Figure 2
Time weighted average (TWA) clearance of (a) β2 microglobulin (beta2mic), (c) urea and (d) creatinine by convective and diffusive transport Time weighted average (TWA) clearance of (a) β2 microglobulin (beta2mic), (c) urea and (d) creatinine by convective and diffusive transport. (b) 
Beta2mic adsorptive clearance during continuous veno-venous hemofiltration (CVVH) and continuous veno-venous dialysis (CVVHD). Data are 
expressed as median and interquartile range. None of these comparisons reaches statistical significance.Critical Care    Vol 10 No 2    Ricci et al.
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the time weight average, the difference was not statistically
significant. Although we can speculate that with a larger sam-
ple size we might have achieved a significant p value, we must
remark that the higher degree of continuity allowed by diffusive
treatments and the consequent lower downtime, when
reported for two independent populations, might further bal-
ance this difference in the clearance of middle molecular
weight molecules. Moreover, irregardless of which modality
was used, the performance of the membranes in removing
small and middle molecular weight solutes was good up to 48
hours.
In light of these results, if a 35 ml/kg/h dose is prescribed dur-
ing a continuous treatment with polyacrylonitrile membranes,
hemofiltration and hemodialysis seem to be equipotent at
clearing low and middle molecular weight solutes. During dial-
ysis, we noticed a significant reduction in β2m clearance at the
72nd hour. Our strict anticoagulation protocol was designed
to infuse as little heparin as possible, aiming to reduce bleed-
ing events. When examined in the light of new anticoagulation
strategies that report filter lifespans of over 100 hours [17], fil-
ter performance could probably be prolonged beyond the limit
of 48 to 72 hours. Based on our results, the impact of adsorp-
tion on overall clearance of β2m was modest, always being
less than 0.01%. Changes in adsorption over time were
insignificant.
Some limits of the study must be addressed. The sample size
was limited to only 15 patients because it showed a good dis-
criminative power to detect differences in filter lifespan; a big-
ger sample might cause the difference in β2m clearance
between CVVH and CVVHD to increase. Secondly, we used
only polyacrylonitrile filters because they are one of the most
commonly used biosynthetic membranes worldwide: our
results can not be extended to other hemodialyzers. Finally,
β2m was chosen as a surrogate for cytokines and other 10 to
50 kDa molecules because it could be easily measured at our
center: however, actual clearance of middle molecular weight
mediators, which share a similar molecular weight but different
biochemical properties, may differ greatly from β2m.
Conclusion
In a cohort of 15 critically ill patients requiring extracorporeal
purification, polyacrylonitrile filters during continuous hemofil-
tration and continuous hemodialysis delivered at 35 ml/kg/h
are comparable for the removal of small and middle molecular
weight solutes. CVVHD appears to warrant longer CRRT ses-
sions. The capacity of both modalities for removing such mol-
ecules is maintained up to 48 hours.
Figure 3
Behaviour of (a) β2 microglobulin (beta2mic), (b) creatinine and (c)  urea clearance over time for continuous veno-venous hemofiltration  (CVVH) and continuous veno-venous dialysis (CVVHD) Behaviour of (a) β2 microglobulin (beta2mic), (b) creatinine and (c) 
urea clearance over time for continuous veno-venous hemofiltration 
(CVVH) and continuous veno-venous dialysis (CVVHD). Beta2mic 
removal decreased significantly with respect to baseline during 
CVVHD at T4 (72 hours). Data are expressed as median and interquar-
tile range. The asterisk indicates p < 0.05.
Key messages
•  CVVHD appears to warrant longer CRRT sessions than 
CVVH.
•  Polyacrylonitrile filters during CVVH and CVVHD deliv-
ered at 35 ml/kg/h are comparable for the removal of 
small and middle molecular weight solutes.
•  The capacity of both modalities for removing such mole-
cules is maintained up to 48 hours.Available online http://ccforum.com/content/10/2/R67
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